585例RAS阳性甲状腺结节中恶性肿瘤的临床与分子预测因素及手术结局
单机构回顾性分析585例经ThyroSeqv3检测的RAS阳性甲状腺结节,术后24%良性、25%为NIFTP、51%为癌。孤立KRAS突变者癌/NIFTP比例低于NRAS或HRAS;拷贝数改变、超声结节大小及更高Bethesda分类与癌/NIFTP相关。孤立RAS阳性肿瘤复发/持续病率极低,非手术结节显著生长率低。
要点
- RAS阳性结节术后癌/NIFTP比例:孤立KRAS 34%,孤立NRAS 74%,孤立HRAS 81%(p<0.0001)。
- 多变量分析中拷贝数改变(OR 12,p=0.02)、超声结节大小(OR 1.3,p=0.003)及Bethesda IV/V/VI与癌/NIFTP相关。
- 孤立RAS阳性癌复发/持续病率1/133(0.8%),非手术结节显著生长6/55(11%)。
核心结论
- 在这大系列RAS阳性肿瘤中,分子和临床因素可预测癌。
- 孤立RAS阳性肿瘤复发/持续病率很低,非切除结节显著生长率低,作者认为这些结节可考虑行肺叶切除术,部分病例甚至可非手术治疗。
研究设计与样本
- 单机构回顾性分析2018-2024年连续RAS阳性甲状腺结节,经ThyroSeqv3检测并有组织病理学或≥1年随访超声。
- 共识别585例有手术病理的RAS阳性结节和55例未切除结节。
主要发现
- 术后140/585(24%)结节为良性,149/585(25%)为NIFTP,296/585(51%)为癌。
- 癌/NIFTP比例在孤立KRAS突变结节为34%,低于孤立NRAS的74%或孤立HRAS的81%(p<0.0001)。
- 多变量分析中,拷贝数改变(OR 12,p=0.02)、超声结节大小(OR 1.3,p=0.003)及更高Bethesda分类(IV、V或VI)与癌/NIFTP相关。
- 中位随访2.5年(IQR 1.2-4),19/272(7%)癌症患者出现持续/复发疾病;合并高风险突变者14/28(50%)高于无高风险突变者5/244(2%),p<0.0001;孤立RAS癌中更低,为1/133(0.8%)。
- 中位2.3年(IQR 1.5-4.5)后,6/55(11%)未切除结节显著生长。
临床怎么用
- 作者认为孤立RAS阳性肿瘤可考虑行肺叶切除术,部分病例甚至可非手术治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: RAS mutations are detected in a wide spectrum of thyroid tumors and when found on FNA biopsy, surgery is typically indicated. OBJECTIVE: To identify clinical and molecular predictors of malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in a consecutive series of RAS-positive thyroid nodules with known surgical outcome. METHODS: We performed a single institution retrospective analysis of a consecutive series of RAS-positive thyroid nodules detected using ThyroSeqv3 and with either histopathology or ≥1 year follow-up ultrasound (2018-2024). RESULTS: Totally, 585 RAS positive nodules with surgical pathology and 55 non-resected nodules were identified. After surgery 140/585 (24%) of nodules were benign, 149/585 (25%) NIFTP, and 296/585 (51%) cancer. The rate of cancer/NIFTP was lower in nodules with isolated KRAS mutations (34%) compared to isolated NRAS (74%) or HRAS (81%) (p<0.0001). The presence of copy number alterations (CNA) (OR 12, p=0.02), nodule size on ultrasound (OR 1.3, p=0.003) and higher Bethesda classification (IV, V or VI) were associated with cancer/NIFTP on multivariable analysis. On median follow-up of 2.5 years (IQR 1.2-4), persistent/recurrent disease occurred in 19/272 (7%) patients with a cancer diagnosis and was more likely with concurrent high-risk mutations (14/28, 50%) vs without (5/244, 2%), p<0.0001, with an even lower rate among isolated RAS cancers (1/133, 0.8%). After median 2.3 years (IQR 1.5-4.5), 6/55 nodules (11%) had significant growth. CONCLUSIONS: In this large series of RAS-positive tumors molecular and clinical factors predicted cancer. In isolated RAS-positive tumors, the rate of recurrent/persistent disease was very low with low rates of significant growth in non-resected nodules, suggesting that these nodules may be managed with lobectomy, and in select cases, even non-surgically.
引用
- Doerfler WR, Argueta AS, Nikitski AV, et al. Clinical and Molecular Predictors of Malignancy in a Series of 585 RAS-positive Thyroid Nodules with Surgical Outcome. J Clin Endocrinol Metab. 2026. PMID: 42995246. doi:10.1210/clinem/dgag452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。